Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1215 is an investigational prophylactic vaccine developed to prevent infection with the Nipah virus (NiV), a zoonotic pathogen that can cause severe respiratory and neurological disease in humans, often leading to high mortality. The vaccine uses a messenger RNA (mRNA) platform, similar to that used in several approved COVID-19 vaccines. It encodes antigens from the Nipah virus designed to stimulate an immune response and generate protective immunity against NiV infection. The development of mRNA-1215 is part of pandemic preparedness efforts targeting emerging infectious diseases for which no licensed vaccines or treatments currently exist[1][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mRNA-1215.